Antibody against a complex between human GARP and latent TGF-β

Patent metadata

Field	Value
Publication number	US-10604579-B2
Application number	US-201815975493-A
Country	US
Kind code	B2
Filing date	May 9, 2018
Priority date	Aug 1, 2013
Publication date	Mar 31, 2020
Grant date	Mar 31, 2020

Abstract

The present invention relates to a protein binding to GARP in the presence of TGF-β and uses thereof.

First claim

The invention claimed is:

1. An antibody that binds to a complex of human Glycoprotein A repetitions predominant (hGARP) and latent TGFβ 1 , wherein the antibody binds to an epitope wherein the antibody comprises the residues Y137, S138 and G138 of the hGARP amino acid sequence of SEQ ID NO: 1 and wherein the antibody is a monoclonal IgG antibody comprising
heavy chains each comprising a variable region comprising the following CDRs:
a VH-CDR1 having an amino acid sequence of: SYYID (SEQ ID NO:13);
a VH-CDR2 having an amino acid sequence of: RIDPEDGGTKYAQKFQG (SEQ ID NO:14) or any amino acid sequence having a single amino acid replacement substitution to the sequence of SEQ ID NO:14;
a VH-CDR3 having an amino acid sequence of: NEWETVVVGDLMYEYEY (SEQ ID NO:15) or any amino acid sequence having a single amino acid replacement substitution to the sequence of SEQ ID NO:15, and

light chains each comprising a variable region comprising the following CDRs:
a VL-CDR1 having an amino acid sequence of: QASQSISSYLA (SEQ ID NO:31);
a VL-CDR2 having an amino acid sequence of: GASRLKT (SEQ ID NO:32);
a VL-CDR3: having an amino acid sequence of QQYASVPVT (SEQ ID NO:33).

2. The antibody of claim 1 , wherein the antibody is a humanized antibody.

3. A pharmaceutical composition comprising the antibody of claim 1 and a pharmaceutically acceptable excipient.

4. An antibody or antigen binding fragment produced by a hybridoma registered under the accession number LMBP 10246CB on May 30, 2013.

5. The antibody of claim 1 , wherein the antibody comprises a CH1 domain, hinge region, CH2 domain, and CH3 domain of a human IgG4.

Assignees

• Ludwig Inst For Cancer Res Ltd
• Univ Catholique Louvain
• Argenx Bvba

Inventors

• Lucas Sophie
• Coulie Pierre
• Cuende Villasur Julia
• Dumoutier Laure
• Renauld Jean-Christophe
• Van Der Woning Sebastian
• Saunders Michael
• De Haard Hans
• De Boeck Gitte

Classifications

• C07K2317/41

  Glycosylation, sialylation, or fucosylation · CPC title

• C07K16/2863 Primary

  against receptors for growth factors, growth regulators · CPC title

• C07K2317/33

  Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity · CPC title

• C07K2317/76

  Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title

• C07K2317/515

  Complete light chain, i.e. VL + CL · CPC title